Key Publications
-
Thura, M., Ye, Z., Al-Aidaroos, A.Q., Xiong, Q., Gupta, A., Li, J., Guo, K., Ang, K. H., and Zeng, Q. (2021) PRL3 induces Polyploid Giant Cancer Cells Eliminated by PRL3-zumab to reduce tumor relapse. Communication Biology 4:932
-
Thura, M., Al-Aidaroos, A.Q., and Zeng, Q. (2019) PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Nature Communication 10:2484.
-
Chong, P.S.Y., Zhou, and Chng. W,J. (2019) Non-canonical activation of β-catenin by PRL-3 phosphatase in acute myeloid leukemia. Oncogene 38:1508-1519.
-
Zhou, J., Toh, S.H., and Chng, W.J. (2018) A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase. J Hematol Oncol. 11:36.
Our innovative antibody drugs provide new hope to
hard-to-treat cancer patients.
CONTACT US
Top